Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-22
2007-05-22
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S237000
Reexamination Certificate
active
10523412
ABSTRACT:
The compounds of formula Iin which the substituents have the meanings as indicated in the description, are novel effective PDE4 inhibitors.
REFERENCES:
patent: 5376656 (1994-12-01), Amschler
patent: 5716954 (1998-02-01), Wilhelm et al.
patent: 6103718 (2000-08-01), Sterk
patent: 6255303 (2001-07-01), Sterk et al.
patent: 6380196 (2002-04-01), Ulrich et al.
patent: 6544993 (2003-04-01), Sterk
patent: 6756371 (2004-06-01), Sterk
patent: 2003/0195215 (2003-10-01), Sterk
patent: 2004/0067946 (2004-04-01), Grundler et al.
patent: 2004/0127707 (2004-07-01), Sterk
patent: 2004/0132721 (2004-07-01), Grundler et al.
patent: 0 763 534 (1997-03-01), None
patent: 92/06963 (1992-04-01), None
patent: 93/07146 (1993-04-01), None
patent: 94/12461 (1994-06-01), None
patent: 98/31674 (1998-07-01), None
patent: 99/31071 (1999-06-01), None
patent: 99/31090 (1999-06-01), None
patent: 99/47505 (1999-09-01), None
patent: 01/19818 (2001-03-01), None
patent: 01/30766 (2001-05-01), None
patent: 01/30777 (2001-05-01), None
patent: 01/94319 (2001-12-01), None
patent: 02/064584 (2002-08-01), None
patent: 02/085885 (2002-10-01), None
patent: 02/085906 (2002-10-01), None
patent: 02/085906 (2002-10-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Coates, W.J., et al., “1,4-Bis(3-oxo-2,3-dihydropyridazin-6-yl)benzene Analogues: Potent Phosphodiesterase Inhibitors and Inodilators”,J. Med. Chem., vol. 33, pp. 1735-1741, (1990).
Sotelo, E., et al., “Pyridazines. Part 25: Efficient and selective deprotection of pharmacologically useful 2-MOM-pyridazinones using Lewis acids”,Tetrahedron Letters, vol. 42, pp. 8633-8636, (2001).
Van der May, M., et al., “Novel Selective PDE4 Inhibitors. 1. Synthesis, Structure-Activity Relationships, and Molecular Modeling of 4-(3,4-Dimethoxyphenyl)-2H-phthalazin-1-ones and Analogues”,J. Med. Chem., vol. 44, pp. 2511-2522, (2001).
Van der May, M., et al., “Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure-Activity Relationships of 4-Aryl-Substituted cis-Tetra- and cis-Hexahydrophthalazinones”,J. Med. Chem., vol. 44, pp. 2523-2535, (2001).
Van der May, M., et al., “Novel Selective Phosphodiesterase (PDE4) Inhibitors. 4. Resolution, Absolute Configuration, and PDE4 Inhibitory Activity of cis-Tetra- and cis-Hexahydrophthalazinones”,J. Med. Chem., vol. 45, pp. 2526-2533, (2002).
Van der May, M., et al., “Novel Selective PDE4 Inhibitors. 3. In Vivo Antiinflammatory Activity of a New Series of N-Substituted cis-Tetra- and cis-Hexahydrophthalazinones”,J. Med. Chem., vol. 45, pp. 2520-2525, (2002).
Altana Pharma AG
Goldberg Joshua B.
Habte Kahsay
McGee Sheldon M.
The Nath Law Group
LandOfFree
Pyrrolidinedione substituted piperidine-phthalazones as PDE4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidinedione substituted piperidine-phthalazones as PDE4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidinedione substituted piperidine-phthalazones as PDE4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3814851